Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 8/20 | 0.39 |
| ▸ | ADRA2A | P08913 | 7/20 | 0.39 |
| ▸ | NPY5R | Q15761 | 7/20 | 0.39 |
| ▸ | JAK2 | O60674 | 3/20 | 0.37 |
| ▸ | JAK1 | P23458 | 3/20 | 0.37 |
| ▸ | JAK3 | P52333 | 3/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.35 |
| ▸ | KDM1A | O60341 | 3/20 | 0.35 |
| ▸ | TDO2 | P48775 | 1/20 | 0.34 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.34 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.33 |
| ▸ | USP1 | O94782 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13620394 | 0.92 | JAK2 (0.37) | MCHR1ADRA2ANPY5RJAK2JAK1 | |
| SCHEMBL13620383 | 0.91 | JAK2 (0.40) | MCHR1ADRA2ANPY5RJAK2JAK1 | |
| SCHEMBL13620500 | 0.91 | KDM1A (0.37) | JAK2JAK1JAK3KDM1ATDO2 | |
| SCHEMBL13620426 | 0.90 | USP1 (0.41) | MCHR1ADRA2ANPY5RJAK2JAK1 | |
| SCHEMBL13620298 | 0.90 | USP1 (0.41) | MCHR1ADRA2ANPY5RJAK2JAK1 | |
| SCHEMBL13620275 | 0.87 | USP1 (0.38) | MCHR1ADRA2ANPY5RJAK2JAK1 | |
| SCHEMBL13620493 | 0.87 | USP1 (0.38) | MCHR1ADRA2ANPY5RJAK2JAK1 | |
| SCHEMBL13620487 | 0.86 | JAK2 (0.34) | JAK2JAK1JAK3KDM1AUSP1 | |
| SCHEMBL13620260 | 0.84 | MCHR1 (0.41) | MCHR1ADRA2ANPY5RKDM1ATDO2 | |
| SCHEMBL3848468 | 0.83 | MCHR1 (0.42) | MCHR1ADRA2ANPY5RKDM1ATDO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090281075-A1 | ISOMERIC PURINONES AND 1H-IMIDAZOPYRIDINONES AS PKC-THETA INHIBITORS | PHARMACOPEIA, INC. (US) | 2009-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281075-A1 | ISOMERIC PURINONES AND 1H-IMIDAZOPYRIDINONES AS PKC-THETA INHIBITORS | PRKCE, PRKCZ, PRKCQ | MCHR1 3804/4885ADRA2A 461/4885NPY5R 3514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.